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KAJIAN FITOKIMIA, AKTIVITI ANTI-TOKSOPLASMOSIS DAN 
AKTIVITI ANTIMALARIA EKSTRAK METANOL TINOSPORA CRISPA 
MIERS DAN FRAKSI BIOAKTIFNYA 
 
ABSTRAK 
 
Toksoplasmosis dan malaria merupakan dua penyakit serius yang mengakibatkan 
bebanan terhadap kesihatan manusia. Pada masa kini, tiada banyak kemajuan yang 
dicapai bagi pembangunan agen-agen kimoterapeutik untuk rawatan toksoplasmosis 
dan malaria. Agen-agen kimoterapeutik semasa telah digunakan selama beberapa 
dekad dan parasit telah mencapai rintangan terhadap ubat-ubatan semasa. Secara 
tradisi, Tinospora crispa Miers telah digunakan dengan meluas untuk merawat 
malaria, demam dan penyakit-penyakit parasit lain yang berkaitan. Dalam kajian ini, 
ekstrak mentah metanol dan fraksi-fraksi bioaktif Tinospora crispa Miers dikaji 
untuk aktiviti-aktiviti anti-parasitik terhadap Toxoplasma gondii dan Plasmodium 
berghei, kajian fitokimia dan aktiviti anti-oksida. Ekstrak mentah telah diekstrak 
daripada batang Tinospora crispa Miers menggunakan kaedah rendaman dan 
dipencilkan kepada kumpulan komponen yang kecil dengan menggunakan teknik 
kromatografi lajur dengan pengelusi sistem pelarut heksana-aseton. Aktiviti 
sitotoksik ekstrak mentah dan kesemua fraksi yang mempunyai kekutuban berbeza 
(F1 hingga F8 masing-masing) telah ditentukan dengan in vitro assai MTT ke atas sel 
Vero. Kajian ini mendapati bahawa ekstrak mentah dan kesemua fraksi menunjukkan 
tiada aktiviti sitotoksik ke atas sel Vero. Ekstrak mentah dan kesemua fraksi telah 
dikaji selanjutnya untuk aktiviti anti-parasitik terhadap Toxoplasma gondii. Ekstrak 
mentah menunjukkan aktiviti perencatan terhadap Toxoplasma gondii dengan nilai 
EC50 7.83 ± 0.12 µg/mL. Daripada kesemua fraksi, fraksi F3 dan fraksi F4 
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menunjukkan aktiviti paling bioaktif terhadap T. gondii dengan nilai EC50 6.77 ± 
0.03 µg/mL dan 6.04 ± 0.02 µg/mL, masing-masing. Siasatan lanjut untuk aktiviti 
antimalaria terhadap Plasmodium berghei dalam model tikus secara in vivo 
dijalankan dengan ekstrak mentah dan dua fraksi poten F3 dan F4 yang telah 
ditentukan daripada kajian in vitro. Tikus dijangkiti dengan malaria yang menerima 
dos rawatan 100 mg/kg berat haiwan ekstrak mentah, fraksi F3 dan fraksi F4 masing-
masing, menunjukkan tahap perencatan parasitemia yang signifikan berbanding 
dengan kawalan positif klorokuin. Tahap perencatan parasitemia bagi dos 100 mg/kg 
berat haiwan fraksi F4 adalah lebih tinggi daripada ekstrak mentah dan fraksi F3 
pada hari ke-6 selepas jangkitan, iaitu pada 54.32 ± 0.24 %, 42.85 ± 0.58 % dan 
41.01 ± 0.46 % masing-masing, berbanding dengan kawalan positif klorokuin yang 
ditentukan pada 97.17 ± 0.03 %. Tambahan pula, tikus dijangkiti malaria yang 
menerima dos rawatan 100 mg/kg berat haiwan fraksi F4 menunjukkan kadar 
kehidupan harian yang lebih tinggi berbanding dengan tikus yang menerima rawatan 
dos rawatan 100 mg/kg berat haiwan ekstrak mentah dan fraksi F3. Komposisi kimia 
fraksi F4 yang bioaktif telah ditentukan dengan menggunakan kajian spektroskopi 
dan kromatografi (TLC, FT-IR, Uv-vis, HPLC, prep-LC dan MS). Komposisi kimia 
daripada fraksi F4 yang berpotensi telah ditentukan secara kualitatif menggunakan 
ESI-MS. 13(S)-HPODE telah didapati wujud dalam fraksi F4. Dalam aktiviti anti-
oksida, ekstrak mentah menunjukkan aktiviti yang lebih tinggi berbanding dengan 
fraksi F3 dan fraksi F4 dalam asai DPPH, asai pelunturan beta-karotena/asid linolik 
dan asai kuasa penurunan. Namun, jumlah kandungan fenolik dalam ekstrak mentah 
adalah 1.6 kali lebih rendah berbanding dengan fraksi F4. Tambahan pula, jumlah 
kandungan flavanoid dalam ekstrak mentah adalah 14.8 kali lebih rendah berbanding 
dengan fraksi F4.  Sebagai kesimpulannya, kajian ini telah mendapati ketinggian 
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potensi ekstrak Tinospora crispa Miers dalam aktiviti-aktiviti anti-toksoplasmosis 
dan antimalaria, di mana Fraksi F4 yang bioaktif telah menyerlahkan aktiviti 
farmakologi signifikan dalam assai anti-T. gondii in vitro dan model tikus P. berghei 
secara in vivo.  Kajian ini membuka ruang kajian selanjutnya yang akan 
memberangsangkan pembangunan praklinikal agen anti-parasitik daripada sumber 
tumbuhan ubatan tempatan. 
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PHYTOCHEMICAL STUDY, ANTI-TOXOPLASMOSIS AND 
ANTIMALARIAL ACTIVITIES OF TINOSPORA CRISPA MIERS 
METHANOL EXTRACT AND ITS BIOACTIVE FRACTIONS 
 
ABSTRACT 
 
Toxoplasmosis and malaria are two serious illnesses resulting in huge toll on human 
health. To date, there is not much advancement in the chemotherapeutic agents used 
to treat toxoplasmosis and malaria. The current chemotherapeutic agents have been 
used for decades and the associated parasites have developed resistance towards the 
current mainstay drugs. Traditionally, Tinospora crispa Miers are widely used to 
treat malaria, fever and some other parasite-related illnesses. In this work, the crude 
methanol extract and bioactive fractions of Tinospora crispa Miers were studied for 
anti-parasitic activities against Toxoplasma gondii and Plasmodium berghei, 
phytochemical content and antioxidant activities. The crude extract was extracted 
from stems of Tinospora crispa Miers using maceration method and further 
fractionated into smaller group of components by elution with the hexane-acetone 
solvent system on column chromatographic technique. The cytotoxic activity of the 
crude extract and all the differing polarity fractions (F1 to F8 respectively) on Vero 
cell line was determined by in vitro MTT assay. This study found that the crude 
extract and all the fractions showed no cytotoxic activity on Vero cells. The crude 
extract and all fractions were then further investigated for anti-parasitic activity 
against Toxoplasma gondii. The crude extract showed inhibitory activity against T. 
gondii with EC50 value of 7.83 ± 0.12 µg/mL. Of all the fractions, fractions F3 and 
F4 showed the most bioactive activity against T. gondii with EC50 values of 6.77 ± 
0.03 µg/mL and 6.04 ± 0.02 µg/mL, respectively. Further investigation for 
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antimalarial activity against Plasmodium berghei in the in vivo mice model was then 
carried out with crude extract and its two potent fractions F3 and F4 determined from 
the in vitro study. Malarial-infected mice receiving treatment of dose at 100 mg/kg 
animal weight of crude extract, fraction F3 and fraction F4 respectively, showed 
significant parasitaemia suppression level as compared to positive control 
chloroquine. The parasitaemia suppression levels of 100 mg/kg animal weight dose 
of Fraction F4 was found to be higher compared to the crude extract and fraction F3 
on Day 6 post-inoculation, which were 54.32 ± 0.24 %, 42.85 ± 0.58 % and 41.01 ± 
0.46 %, respectively in comparison with the positive control chloroquine at 97.17 ± 
0.03 %. In addition, malarial-infected mice receiving 100 mg/kg animal weight dose 
of fraction F4 treatment showed higher daily survival rate compared to the mice 
receiving same doses of crude extract and fraction F3.  The chemical composition of 
bioactive fraction F4 was determined by various spectroscopic and chromatographic 
studies (TLC, FT-IR, UV-vis, HPLC, prep-LC and MS). The chemical composition 
of bioactive fraction F4 was determined qualitatively on ESI-MS. The 13(S)-HPODE 
was found to be present in fraction F4. In the antioxidant activities, the crude extract 
showed better activities than fractions F3 and F4 in DPPH assay, beta 
carotene/linoleic acid bleaching assay and reducing power assay. However, the total 
phenolic content of the crude extract was 1.6 times lower compared to fraction F4, 
while the total flavonoids content of the crude extract was 14.8 times lower than 
fraction F4. In conclusion, this study have uncovered potent anti-toxoplasmosis and 
antimalarial activities of Tinospora crispa Miers extract, where its bioactive fraction 
F4 exhibited significant pharmacological activities in the in vitro anti-T. gondii assay 
and in vivo P. berghei mice model. This work opens the door to further promising 
pre-clinical development of anti-parasitic agent(s) of local medicinal plant origin.
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Apicomplexan Parasites 
A parasite refers to an organism that lives on or in a host, and gets its food from or at 
the expense of its host (CDC, 2014). Pathogenic parasites can cause serious diseases 
in humans and many economically important animal species. One of the important 
classifications of the parasite is the apicomplexan parasites that consist of pathogenic 
single-cell intracellular parasites. Some important apicomplexan parasites that cause 
diseases in human are Plasmodium species that is well known for the deadly malaria, 
Cryptosporidium species for causing cryptosporidiosis and Toxoplasma species for 
causing toxoplasmosis. Two apicomplexan parasites (Plasmodium and Toxoplasma) 
that cause severe diseases in human population were the main highlights in the study.  
 
All apicomplexan are parasitic and share many specific features related to parasitism 
(Figure 1.1). The most important feature is the presence of the apicoplast (McFadden 
et al., 1996). Apicoplast is a non-photosynthetic organelle of algal origin (Tawk et al., 
2011). However, an exception to this rule is the Cryptosporidium parasites that loss 
the organelle during evolution (Zhu et al., 2000). Several studies have proven that 
the apicoplast fulfils critical functions for parasites invasion and survival. Apicoplast 
is the site of several plastid-derived biochemical pathways such as biosynthesis of 
fatty acids, isoprenoids, haem and iron–sulfur clusters (Ralph et al., 2004). Ralph et 
al. (2004) also stated that the metabolic pathways of the apicoplast contribute to lipid 
production and the modification of lipid-bound proteins. These findings proved that 
the apicoplast plays a crucial role in the successful establishment of parasite-host 
interaction, such as in the formation of parasitophorus vacuole during parasites 
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invasion. Moreover, apicoplast is needed for survival in both erythrocytic (Goodman 
et al., 2007) and liver stages (Vaughan et al., 2009; Yu et al., 2008) of P. falciparum. 
In fact, the apicoplast forms close associations with mitochondria and endoplasmic 
reticulum (ER) during development of Plasmodium species (van Dooren et al., 2005), 
while in Toxoplasma gondii, apicoplast is tightly associated with ER (Tomova et al., 
2009).  
 
Apart from the apicoplast, the apicomplexan parasites also have a characteristically 
polarized cell structure, complex cytoskeletal and secretory organelle at the apical 
end of the cell (Dubey et al., 1998). The cytoskeleton and organelles mediate the 
parasites' locomotion and cellular invasion (Templeton et al., 2004). Apicomplexan 
parasites also contain the rhoptries and micronemes that are deployed during the 
invasion process and the delivery of parasites protein into the host cells 
(Anantharaman et al., 2007). 
 
Each apicomplexan lineage has evolved unique spectrum of protein that modify the 
host in diverse ways. The mechanisms of invasion into the hosts are largely 
conserved among the apicomplexan (Kim and Weiss, 2004). However, the host range, 
cell specificity and life cycle stages within species are quite different among the 
apicomplexan parasites. 
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Figure 1.1: The morphology of apicomplexan parasites. Apicomplexan parasites are 
highly polarized cells containing a collection of organelles that are specific to the 
phylum. The figure was adapted from Morrissette and Sibley (2002). 
 
 
1.1.1 Toxoplasma gondii 
Toxoplasma gondii is an obligate intracellular protozoan parasite which is a 
significant human and veterinary pathogen (Kim and Weiss, 2004). Figure 1.2 
illustrates the ultra structure of a T. gondii tachyzoite. T. gondii is capable to infect 
any nucleated mammalian or avian cell including humans (Dubey, 1998). This makes 
T. gondii one of the most successful parasitic organisms worldwide and can be found 
in most regions of the world (Innes, 2010). Felidae (cat) species are the definitive 
host of T. gondii for its reproductive cycle while the other warm-blooded organisms 
such as humans serve as intermediate hosts for its propagation.  
 
The apicomplexan parasite Toxoplasma gondii causes a flu-like disease known as 
toxoplasmosis. The symptoms of toxoplasmosis include fever, headache, sore throat, 
cough and dizziness. Toxoplasmosis can also cause significant morbidity and 
mortality in the fetus and immunocompromised individuals if not treated (Montoya 
and Liesenfeld, 2004). According to Flegr et al. (2014), infection with T. gondii is 
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the most prevalent one in humans, which estimated to affect about 30-50 % of the 
world population. On top of that, there was a T. gondii seroprevalence of 55.7 % 
among rural Malays in a study from Malaysia (Petersen, 2007). In addition, 
estimation of toxoplasmosis disease burden ranks this disease at the same level as 
salmonellosis or campylobacteriosis in the food borne disease category (Kijlstra and 
Jongert, 2008). 
 
Numerous researchers supported the use of T. gondii parasite as the model organism 
to study the apicomplexan parasites. The advantages of using T. gondii as model 
organism lays in its various biotechnology establishments that includes the well-
established methodology for classic and reverse genetics of T. gondii (Roos et al., 
1999), identification of numerous T. gondii molecular markers and the relative ease 
with which the parasite can be studies using microscopic techniques (Kim and Weiss, 
2004). All these factors make T. gondii the best model system for cell biology 
investigation of apicomplexan parasites. The studies of mechanisms of drug 
resistance, the biology of the apicoplast, and the process of host cell invasion have all 
been achieved in T. gondii (Kim and Weiss, 2004). In fact, T. gondii is the most 
experimentally tractable among the apicomplexan parasites (Roos et al., 1999).  
 
Table 1.1: Taxonomic classification of Toxoplasma gondii (Adapted from NCBI, 
2015a). 
Taxonomic Classification 
Kingdom Alveolata 
Phylum Apicomplexa 
Class Conoidasida 
Order Eucoccidiorida 
Family Sarcosystidae 
Genus Toxoplasma 
Species T. gondii 
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Figure 1.2: Ultra structure comparisons of a T. gondii tachyzoite and a P. falciparum 
merozoite (adapted from Baum et al., 2006). 
 
 
1.1.1.1 Life Cycle and Transmission of Toxoplasma gondii 
The life cycle and transmission routes of T. gondii are illustrated in Figure 1.3. The 
life cycle of T. gondii is facultatively heteroxenous. This means that T. gondii has 
more than one host in its life cycle. There are three infectious stages of T. gondii 
during their life cycle and they are tachyzoites, bradyzoites contained in tissue cysts 
and sporozoites contained in sporulated oocysts. All the three stages are infectious 
for both intermediate and definitive hosts (Tenter et al., 2000).  
 
The sexual reproduction of T. gondii only occurs in the felid's intestinal tract. The 
cats become infected after consuming intermediate hosts contaminated with tissue 
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cysts or oocysts-contaminated water (Montoya and Liesenfeld, 2004). Next, the 
parasites invade the cat enterocytes and undergo division and differentiation into 
microgametocytes and macrogametocytes. The gametocytes fuse to form zygotes or 
oocysts that are shed into environment together with cat feces. The oocysts produce 
highly infectious sporozoites that are very resistant to environmental damage. The 
sporozoites may persist for years in warm and humid condition (Montoya and 
Remington, 2000). The oocysts spread and contaminate the water, soil, fruits and 
vegetables. Animals (intermediate hosts) will be infected following the consumption 
of contaminated water, soil, fruits or vegetables (Tenter et al., 2000). 
 
The asexual reproduction of T. gondii occurs in intermediate hosts (Montoya and 
Liesenfeld, 2004). Shortly after ingestion, the oocysts are rapidly transformed into 
tachyzoites. Tachyzoites enter all nucleated cells and replicate rapidly within the 
cells. Replication of the tachyzoites inside the cells eventually leading to cell death. 
Once the host cells are disrupted, the tachyzoites are released and disseminated via 
the bloodstream and rapidly invades many tissues such as central nervous system 
(CNS), skeletal muscle, heart, eye, placenta and fetus (Montoya and Liesenfeld, 
2004). The tachyzoites cause massive tissue destruction, stimulate host immune 
system and cause clinical manifestations of the disease (Montoya and Remington, 
2000). 
 
Under the pressure of the immune response, tachyzoites can transform into 
bradyzoites to form cysts that reside and persist in tissues and muscles, especially in 
brain, skeletal and heart muscles for the life of the host (Montoya and Liesenfeld, 
2004). The bradyzoites can be released and transformed back into active tachyzoites 
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that cause recrudescence infection. The cysts are the infective stages for both 
intermediate and definitive hosts (Montoya and Remington, 2000). 
 
Transmission of T. gondii in human can occur via several routes. The main route is 
through oral consumption (Montoya and Liesenfeld, 2004). This happens when 
eating raw or undercooked cysts-contaminated meat, foods or water contaminated 
with cat feces or environmental samples such as fecal-contaminated soil, changing 
the litter box of pet cat, unwashed fruits or vegetables and unfiltered water. There 
was high seroprevalence of T. gondii in countries and regions where the humans 
were common to eat undercooked or raw meat (Dubey and Beattie, 1988). Second, 
humans can acquire toxoplasmosis during blood transfusion or organ transplantation 
(Montoya and Liesenfeld, 2004). However, the risk of transmission through this 
route is very low (Dubey and Beattie, 1988). Lastly, the fetus can get infected with T. 
gondii through transplacental infection from the pregnant mother (Montoya and 
Remington, 2000). 
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Figure 1.3: Life cycle, transmission route and clinical manifestations of T. gondii 
(Adapted and modified from Montoya and Liesenfeld, 2004). 
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1.1.1.2 Clinical Manifestations and Pathogenesis of Human Toxoplasmosis 
The clinical manifestations and pathogenesis of toxoplasmosis in humans mainly 
depend on the patient's immune status and the clinical setting such as 
immunocompetent, immunocompromised, congenital toxoplasmosis, or ocular 
disease (Montoya and Liesenfeld, 2004). 
(i) Immunocompetent people 
The primary infection usually causes a self-limited and non-specific flu-like illness. 
The general symptoms of toxoplasmosis are fever, lymphadenopathy, headache, sore 
throat, cough, myalgia and dizziness. However, infection can remain for life and 
reactivation of T. gondii infection can occur when the immune system is 
compromised. Though very rarely, myocarditis, polymyositis, pneumonitis, hepatitis 
or encephalitis can occur as a result of T. gondii infection (Montoya and Liesenfeld, 
2004). 
 
(ii) Immunocompromised and immunosuppressed patients 
Toxoplasmosis can be life-threatening (Liesenfeld et al., 1999) and always happens 
as a result of reactivation of chronic infection in immunocompromised individuals 
(Porter and Sande, 1992). The most common clinical manifestation of toxoplasmosis 
in acquired immunodeficiency syndrome (AIDS) patient is toxoplasmic encephalitis. 
In fact, toxoplasmic encephalitis is the most common cause of death among 
toxoplasmosis patients with AIDS (Dubey, 2004). Other clinical manifestations 
include mental status changes, seizures, focal motor deficits, cranial nerve 
disturbances, sensory abnormalities, cerebellar signs, movement disorders, and 
neuropsychiatric findings (Montoya and Liesenfeld, 2004). Severe manifestations of 
toxoplasmosis may also include chorioretinitis, pneumonitis, or multiorgan 
10 
 
involvement with acute respiratory failure and haemodynamic abnormalities similar 
to septic shock (Liesenfeld et al., 1999). Severe symptoms of toxoplasmosis can also 
be observed in immunosuppressed patients with malignancies and after transfusions 
or transplant with immunosuppressive therapy (Dubey and Jones, 2008). 
 
(iii) Congenital toxoplasmosis 
Infection with T. gondii during pregnancy causes serious consequences. The severity 
of the infection depends on the stage of pregnancy at the time of infection (Montoya 
and Liesenfeld, 2004). The tachyzoites of T. gondii can cross the placenta to infect 
the fetus, thus causing congenital infection. Chances of congenital infection are 10-
25 % in untreated women in the first trimester of pregnancy (Emelia, 2009). The 
incidence of fetal infection ranges between 30-54 % and 60-65 %, respectively, if 
infection occurs during second and third trimester of pregnancy (Lynfield and 
Guerina, 1997). Consequences to fetus are more severe if the infection occurs in 
early stages of pregnancy (Remington and Desmonts, 1990). Some of the 
consequences that might occur include miscarriage, intra-uterine growth retardation 
and premature birth. Moreover, neonatal clinical manifestations of congenital 
toxoplasmosis vary widely. These may include hydrocephalus, microcephaly, 
intracranial calcifications, chorioretinitis, strabismus, blindness, epilepsy, 
psychomotor or mental retardation, petechia due to thrombocytopenia, and anaemia 
(McAuley et al., 1994; Swisher et al., 1994).  
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(iv) Ocular disease 
Toxoplasmic chorioretinitis refers to severe eye infection and it results from 
congenital or postnatally acquired infection of acute infection or reactivation 
(Montoya and Remington, 1996; Holland, 1999). The symptoms include white focal 
lesions in retina with overlying and intense vitreal inflammatory reaction. The retina 
lesion will slowly resolve and leaving a focus of retinochoroidal scarring (Koch et al., 
1943). Besides, mild ocular pain, blurred vision and new onset of floating spots, 
segmental periarteritis, retinal and vitreous haemorrhage, choroidal or retinal 
neovascularization are among other symptoms of active toxoplasmic choretinitis 
(Emelia, 2009).  
 
1.1.1.3 Treatment of Toxoplasmosis 
There is not much advancement in the search for new anti-toxoplasmosis drugs. The 
current mainstay anti-toxoplasmosis agents have been used for decades. The classic 
clinical drug combinations to treat toxoplasmosis are combination of pyrimethamine, 
sulfadiazine and folinic acid (Montoya and Remington, 2000).  
 
The immunosuppressed patients such as recipients of organs transplant need to be 
tested for anti-Toxoplasma antibodies, and highly effective prophylaxis 
trimethoprim/sulfamethoxazole combinations are given (Montoya and Liesenfeld, 
2004). Clindamycin is given to the patients with sulfonamides intolerance.  
 
For women with suspected or confirmed acute T. gondii infection during pregnancy, 
spiramycin treatment is recommended for the first and early second trimester while 
pyrimethamine/sulfadiazine is recommended for late second and third trimester 
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(Gilbert et al., 2001; Gras et al., 2001). Suspected or confirmed maternal infection 
acquired during gestation must be confirmed by prenatal diagnosis by PCR of 
amniotic fluid (Rormand et al., 2001). Prenatal treatment with 
pyrimethamine/sulfadiazine in women suspected or confirmed with fetal infection 
reduces the sequelae of the disease in newborn (Foulon et al., 1999). 
 
Toxoplasmic infection can cause severe eyes infection and the treatment should start 
when severe inflammatory responses, proximity of retinal lesions to the fovea or 
optic disk, or both are found (Holland, 1999). The combination of drugs used is 
pyrimethamine, sulfadiazine and prednisone. Besides, clindamycin or 
trimethoprim/sulfamethoxazole for a minimum of 3 weeks can also be used to treat 
the disease (Luft et al., 1986). Spiramycin is not recommended to treat toxoplasmic 
chorioretinitis due to high recurrence rate (Ghosh et al., 1965).  
 
1.1.1.4 Current Challenges in the Treatment of Toxoplasmosis 
 
The current standard therapies for toxoplasmosis involve the combinations of 
pyrimethamine with sulfadiazine, clindamycin, azithromycin, or atavaquone 
(Djurkovic-Djakovic et al., 1999; Chirgwin et al., 2002). However, these drugs do 
not completely eliminate the intracellular parasite and are often associated with 
severe side effects (Montoya and Liesenfeld, 2004). The combination of 
pyrimethamine and sulfadiazine is not recommended for the treatment of acute 
toxoplasmosis in pregnancy and AIDS patients, as they can cause bone marrow 
suppression, liver toxicity, nausea, vomit, seizures and other symptoms (Haverkos, 
1987). Besides, clindamycin can cause adverse effects such as skin rashes and 
gastrointestinal problems such as diarrhoea, stomach upset and bleeding (Djurkovic-
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Djakovic et al., 1999). However, continuous drug therapy is essential for patients to 
ensure prevention of severe complications.  
 
An effective vaccine against human T. gondii infection is a very desirable measure to 
control the disease. However, the development of effective vaccine is still in early 
stage of research. Alternative drugs with lesser side effects are needed to combat the 
disease. The knowledge of the parasite’s lifecycle, transmission routes, risk groups 
and host immune responses has helped in the development of strategies to control the 
disease, reduce transmission of the parasite and limit environmental contamination. 
 
1.1.2 Plasmodium parasites 
The apicomplexan Plasmodium parasites are the causative agents of the well-known 
malaria disease in humans. Malaria is the most important parasitic disease in human. 
According to World Malaria Report 2013 by World Health Organization (WHO), 
malaria is endemic in 104 countries throughout the world and 3.4 billion people are 
at risk of malaria. An estimated 207 million people suffered from malaria in 2012 
and caused about 627 000 death cases. A total of about 90 % of cases and deaths 
occurred in Sub-Saharan Africa and about 77 % of death cases were in children 
under age of 5. Malaria causes a huge toll on human health and imposes a heavy 
social and economic burden in the developing countries, especially in Sub-Saharan 
Africa and South Asia. In Malaysia, cases of malaria are restricted in distribution. 
Between 2000 and 2012, Malaysia successfully achieved more than 75 % decrease in 
microscopically confirmed malaria cases and more than 50 % decrease in reported 
malaria mortality rate (WHO, 2013). 
 
14 
 
The malaria-causing Plasmodium parasites are transmitted by Anopheles mosquitoes. 
About 30 species out of 400 different species of the Anopheles mosquitoes are the 
important vectors in transmitting the parasites (White et al., 2014). The ultra 
structure of a P. falciparum merozoite is illustrated in Figure 1.2 under Section 1.1.1. 
There are five species of the Plasmodium parasites that cause malarial infections in 
human. Majority of the cases are caused by Plasmodium falciparum or Plasmodium 
vivax, but infection with Plasmodium ovale and Plasmodium malariae can lead to 
malaria as well. Recently, there were cases of malaria caused by monkey malaria 
Plasmodium knowlesi being reported in parts of Southeast Asia (Kantele and 
Jokiranta, 2011). P. falciparum causes the most serious cases of malaria and is 
responsible for almost all malaria death cases. P. falciparum predominates in Africa 
while P. vivax has a wider distribution due to its ability to develop in Anopheles 
mosquito at lower temperatures, and to survive at higher altitudes and in cooler 
climates. Besides, P. vivax also has a long dormant liver stage that enables the 
parasites to persist in human (White et al., 2014). 
 
Malaria remains one of the most important diseases in humans in terms of both 
mortality and morbidity, with Plasmodium falciparum being the most important 
infecting agent (White et al., 2014). The increasing global spread of drug resistance 
to most of the available and affordable antimalarial drugs is a major concern and 
requires innovative strategies to combat (Nguyen-Pouplin et al., 2007).  
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Table 1.2: Taxonomic classification of Plasmodium parasites (Adapted from NCBI, 
2015b) 
Taxonomic Classification 
Kingdom Alveolata 
Phylum Apicomplexa 
Class Aconoidasida 
Order Haemosporida 
Family Plasmodiidae 
Genus Plasmodium 
Species P. falciparum, P. ovale, P. vivax. P. malariae, P. knowlesi 
 
 
1.1.2.1 Life Cycle and Transmission of Plasmodium Parasites 
The life cycle of the Plasmodium parasites involve three distinct stages (Figure 1.4). 
The liver and blood stages occur in host, whereas the sexual stage occurs in the 
mosquito gut (White et al., 2014).  
 
The malaria-infected female anopheline mosquito inoculates motile sporozoites into 
the human host during a blood meal. The sporozoites then rapidly infect and invade 
into hepatocytes. Inside liver cells, the sporozoites mature into schizonts and 
multiply to become merozoites. A successful sporozoite invasion can produce about 
10000 to 30000 merozoites in 5.5-8 days inside a single hepatocyte. In P. vivax and 
P. ovale, infection of sporozoites into liver cells can produce hypnozoites in the 
dormant stage that can persist in the liver, which will then causing relapses weeks or 
years later. Next, the merozoites are released to invade the red blood cells. The 
parasites undergo asexual multiplication in the erythrocytes after the initial liver 
replication. An asexual cycle in the blood takes roughly 48 h for P.  falciparum, P. 
vivax, and P. ovale, 72 h for P. malariae, and 24 h only for P. knowlesi. Inside the 
erythrocytes, the merozoites develop into ring stage trophozoite (Figure 1.5) and then 
mature into daughter merozoites. The erythrocytes rupture and release daughter 
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merozoites which rapidly invade new erythrocytes and repeat the cycle (White et al., 
2014).  
 
The malaria disease is caused by the effects of erythrocytes parasitization and 
destruction, as well as the host immune reaction to fight against the parasites. Inside 
the red blood cells, the merozoites consume the cell content, altering the cell 
membrane to facilitate nutrients transportation and metabolise the toxic haem into 
harmless haemozoin (malaria pigment). Besides, some merozoites differentiate into 
gametocytes, which are then ingested by Anopheles mosquito during blood meal and 
initiate the sexual reproduction cycle of the parasites (Fujioka and Aikawa, 2002). 
 
The sexual reproduction of the Plasmodium parasites occurs only in mosquitoes. 
Upon ingestion of the gametocytes, the microgametocytes fuse with 
macrogametocytes inside the mosquito's stomach to produce zygotes. The zygotes 
are then developed into ookinetes that invade the midgut wall of mosquitoes. 
Ookinetes develop into oocysts that rupture and release the sporozoites. The 
sporozoites migrate to the mosquito's salivary gland and inoculate into new host 
when the mosquito taken a blood meal. Inoculation of sporozoites into new human 
host initiates the new malaria life cycle (Fujioka and Aikawa, 2002). 
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Figure 1.4: Life cycle of Plasmodium parasites in the human body and the 
anopheline mosquito (adapted from White et al., 2014). 
 
 
 
 
 
Figure1.5: Gametocyte and trophozoite (ring form) of P. falciparum in a thin blood 
smear [Adapted from Centers for Disease Control and Prevention (CDC) USA, 
2014]. 
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1.1.2.2 Clinical Manifestations and Pathogenesis of Human Malaria 
Malaria causes severe clinical manifestations in human. The initial symptoms of 
malaria are nonspecific and they include absence of wellbeing, headache, fatigue, 
anaemia, muscle aches, abdominal discomfort and followed by irregular fever. Other 
symptoms such as vomiting, nausea and hypotension also occur frequently. Malaria 
caused by falciparum parasites is also associated with generalised seizures and might 
be followed by coma that is caused by cerebral malaria. For uncomplicated malaria 
infections, most patients have fewer physical symptoms. Since malaria parasites 
infect the liver, hepatomegaly may often be found in young children while mild 
jaundice is more likely to occur in adults. Recurrent malaria infection causes chronic 
anaemia and splenomegaly in young children (White et al., 2014). 
 
Infection with P. falciparum can cause the severe malaria type. In falciparum 
malaria, the infected erythrocytes tend to adhere to vessel walls and also to each 
other. The erythrocytes adherence causes sequestration of red blood cells containing 
mature parasites into vital organs particularly the brain (White et al., 2014). Inside 
the brain, the sequestered parasites will interfere with microcirculatory flow and the 
metabolism and normal functioning of vascular endothelium (Pongponratn et al., 
2003).  The erythrocytes in malaria caused by other parasites species are not 
sequestered substantially. Severe falciparum malaria is mainly attributed by 
extensive parasitised erythrocytes sequestration and consequently dysfunction of 
vital organs. However, age is the main factor determining the manifestation of severe 
falciparum malaria (Dondorp et al., 2008). In children, severe anaemia and 
hypoglycaemia occur more frequently whereas acute pulmonary oedema, acute 
kidney injury, and jaundice are more common in adults. Besides, acidosis and 
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cerebral malaria following by subsequent coma can occur in all age. The mortality 
rate increases as the proportion of infected red blood cells exceeds 2 %. However, 
uncomplicated falciparum malaria has a low mortality rate of about 0.1 % when 
properly treated with effective antimalarial drugs (Dondorp et al., 2008). 
 
Severe malaria can also cause other clinical complications such as invasive bacterial 
infections by enteric bacteria in children (Bronzan et al., 2007). Malaria can 
accelerate the progression and transmission of HIV infection (Kublin et al., 2005). 
The mortality rate of clinical and severe malaria is increased in adults with HIV 
infection and compromised immune status (Whitworth et al., 2000; Chalwe et al., 
2009). Moreover, the concomitant HIV infection increases the severity and mortality 
of severe falciparum malaria in children (Berkley et al., 2000; Hendriksen et al., 
2012). 
 
Falciparum malaria can cause serious complications in pregnant women. The risk of 
low birth weight (< 2.5 kg) increases when the mother get infected. The lower birth 
weight is associated with increased infant mortality (Desai et al., 2007). Other 
malaria complications such as high parasitaemia, severe anaemia, hypoglycaemia 
and acute pulmonary oedema are more frequent in pregnant women compared to 
non-pregnant women (McGready et al., 2012). Fetal distress, premature labour and 
stillbirth often occur in pregnant women with severe malaria (Desai et al., 2007). 
There is a higher risk of infant death if maternal malaria occurs during late 
pregnancy (Bardaji et al., 2011). Besides, maternal death caused by haemorrhage 
during childbirth is correlated with the malaria-induced anaemia (Rijken et al., 
2012). 
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1.1.2.3 Treatment of Malaria 
Most of the antimalarial drugs target the asexual erythrocytic stage of the parasite. 
During parasitic growth, the parasites metabolize haemoglobin. The haemoglobin 
degradation produces free haem that is able to react with oxygen, thus producing 
reactive oxygen species as toxic by-products. A major pathway of haem 
detoxification is through polymerization to malaria pigment haemozoin (Pagola et 
al., 2000). Most of the antimalarial drugs act to disturb the polymerization of haem, 
thus killing the parasites with its own metabolic waste (Egan and Marques, 1999). 
The main chemical classes of antimalarial drugs are as listed in Table 1.3. Some 
antibiotics are also used to treat malaria in combination with other drugs.  
 
The only class of drugs that is active against the gametocytes stage is of 8-
aminoquinolines (Robert et al., 2001) (Table 1.3). Primaquine belongs to 8-
aminoquinolines class and it is widely used against the hypnozoites (liver dormants) 
responsible for causing relapse of P. vivax and P. ovale. Primaquine interferes with 
the mitochondrial function of Plasmodium parasites (Robert et al., 2001). 
 
The classes of sulfonamides and sulfones, biguanides, diaminopyrimidine and 
naphthoquinone act as nucleic acid inhibitors (Table 1.3). Sulfonamides and 
sulfones, biguanides and diaminopyrimidine belong to the folate antagonist class 
(Olliaro, 2001), though the Plasmodium parasites already developed resistance 
against this class of drugs. The inhibition of the enzymes in the folate pathway 
results in decreased synthesis of parasites pyrimidine, thus reduces the formation of 
methionine, serine and DNA necessary for parasites development. The inhibitory 
activity is exerted at all growing stages of the erythrocytic cycle and on young 
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gametocytes (Olliaro, 2001). On the other hand, atovaquone (from class 
naphthoquinone) inhibits the respiratory chain of malarial mitochondria at the 
cytochrome bc1 complex by mimicking the natural substrate, ubiquinone. This, in 
turn, inhibits the mitochondrial electron transfer from ubiquinol to cytochrome c (Fry 
& Pudney, 1992). However, the parasites develop resistance to atovaquone quickly 
when atovaquone is prescribed alone. Therefore, atovaquone is usually prescribed 
with proguanil in fixed combination to treat malaria (Robert et al., 2001). 
     
On the other hand, blood schizonticides refer to drugs that act on erythrocytic stages 
of parasites. The primary target is the parasite food vacuole (Olliaro, 2001). These 
classes of drugs include the quinoline containing drugs such as 4-Aminoquinolines 
and aryl-amino alcohols, as well as the artemisinin-type drugs (Table 1.3). The 
quinoline drugs accumulate in the acidic food vacuole within the parasites, and 
subsequently alter the haem detoxification processes that eventually leading to 
parasites death (Olliaro, 2001).  
 
The artemisinin-type compounds include the natural extract artemisinin and its semi-
synthetic derivatives. They achieve higher parasitaemia reduction rates than any 
other drugs (White, 1997), and are being used for the treatment of uncomplicated and 
severe forms of malaria. The artemisinin-type compounds mainly act through the 
generation of alkylating species by reaction of homolytic cleavage of endoperoxide 
bridge with haem (Robert et al., 2001). The generated alkylating radicals then disrupt 
the vital biochemical processes of the parasite via alkylation of biomolecules and 
thus causing parasites death (Robert et al., 2001). 
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Artemisinin-based combination therapies (ACTs) are the current first-line therapy for 
falciparum malaria in all endemic areas (WHO, 2013). It is also highly efficacious 
against the other human malarias. Artemisinin combination treatment acts rapidly 
and reliably effective. Artemisinin combination therapy has few adverse effects and 
has very high curative level (International Artemisinin Study Group, 2004). In ACTs, 
the artemisinin derivatives are combined with a partner drug of different mechanisms 
of action. The fast-acting artemisinin compound serves the purpose to reduce the 
main parasite load during the first three days of treatment, while the partner drug 
eliminates the remaining parasites (WHO, 2013). The artemisinin derivatives such as 
artesunate is also the first treatment of choice for all types of severe malaria (severe 
falciparum, vivax and knowlesi malaria) as artesunate has no important local or 
systemic adverse effects (Barber et al., 2013). Chloroquine is still used in regions 
where it still remains efficacious. 
 
Atovaquone–proguanil, doxycycline, primaquine, or mefloquine are prescribed to 
travellers travel to resistant P. falciparum endemic areas as chemoprophylaxis 
purpose. On the other hand, sulfadoxine–pyrimethamine was given as intermittent 
preventive treatment to pregnant women in Africa. A minimum of three doses of 
sulfadoxine–pyrimethamine are recommended to provide continuous preventive 
effects against malaria (White et al., 2014). Besides, mefloquine is recommended for 
chemoprophylaxis in pregnant women travelling to areas with drug-resistant malaria. 
WHO (2012) recommended monthly amodiaquine and sulfadoxine–pyrimethamine 
(maximum four doses) to all children aged 3–59 months in Africa during the yearly 
malaria transmission season. 
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Table 1.3: Classes of chemical family for antimalarial drugs. The table was adapted 
and modified from WHO (2010). 
 
Chemical Family Common structure Drugs 
4-Aminoquinolines 
 
Chloroquine, amodiaquine, 
piperaquine 
Aryl-amino 
alcohols 
 
Quinine, quinidine, 
mefloquine, halofantrine, 
lumefantrine 
Sulfonamides and 
sulfones  Sulfonamides 
 
     Sulfones 
Sulfadoxine, sulfalene, 
dapsone 
Biguanides 
 
Proguanil, chlorproguanil 
Diaminopyrimidine 
 
Pyrimethamine, cycloguanil 
8-Aminoquinoline  Primaquine 
 
 
Sesquiterpene 
lactones 
 
Artemisinin, arteether, 
artemether, artesunate, 
dihydroartemisinin 
 
Naphthoquinone  Atovaquone 
 
 
Antibiotics 
Azythromycin 
 
Clindamycin 
 
Doxycycline 
 
Tetracycline 
Azythromycin, clindamycin, 
doxycycline, tetracycline 
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1.1.2.4 Current Challenges in the Treatment of Malaria 
 
The current antimalarial drugs such as chloroquine and artemisinin have been used 
for decades and there is not much advancement in the search for new effective 
antimalarial molecules. Even the newest antimalarial drugs, the artemisinin 
derivative, were introduced into market in 1990s (Faurant, 2011). 
 
The use of chloroquine to prevent and treat falciparum malaria has led to the wide 
spread appearance of chloroquine-resistance strain of Plasmodium falciparum across 
the world (Rahman et al., 1999). The resistance of malaria parasites has been 
increasingly extended to other current antimalarial drugs. This is because many of 
antimalarial drugs in current usage are chemically related. Thus, development of 
resistance to one drug can facilitate the development of resistance to others. In fact, 
cross-resistance towards chloroquine and amodiaquine (4-aminoquinolines) has been 
reported (Bloland, 2001). Besides, resistance to mefloquine may lead to resistance to 
halofantrine and quinine.  
 
In such situation, World Health Organization (WHO) has recommended artemisinin-
based combination therapies in all endemic countries. Moreover, WHO had also 
banned the use of artemisinin in monotherapy and recommended the artemisinin 
combination therapy instead in order to delay the development of drug resistance and 
to improve cure rates (WHO, 2006; Robert et al., 2001). Recently, there
 
have been 
signs that the efficacy of artemisinin-based combination
 
therapy and artesunate 
monotherapy have declined in western
 
Cambodia. The resistance to artemisinin has 
been reported around Thai-Cambodia border (Muller et al., 2009) and Thailand-
Myanmar border (Phyo et al., 2012). The spread of artemisinin resistance parasites to 
